GERM vs. CANC

Last updated Jun 4, 2026

GERM (Amplify Treatments, Testing and Advancements ETF) and CANC (Tema Oncology ETF) are both Health & Biotech Equities funds. GERM is passively managed, while CANC is actively managed. Over the past year, GERM returned 0.00% vs 47.37% for CANC. GERM charges 0.68%/yr vs 0.75%/yr for CANC.

Performance

GERM vs. CANC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Amplify Treatments, Testing and Advancements ETF (GERM) and Tema Oncology ETF (CANC). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

GERM

• 1D: 0.00%
• 1M: 0.00%
• YTD: 0.00%
• 6M: 0.00%
• 1Y: 0.00%
• 3Y*: —
• 5Y*: —
• 10Y*: —

CANC

• 1D: 0.08%
• 1M: -3.73%
• YTD: 4.82%
• 6M: 3.86%
• 1Y: 47.37%
• 3Y*: 107.76%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

GERM vs. CANC - Yearly Performance Comparison

	2026 (YTD)	2025	2024
GERM Amplify Treatments, Testing and Advancements ETF	0.00%	0.00%	0.00%
CANC Tema Oncology ETF	4.82%	42.92%	-12.26%

GERM vs. CANC - Sectors Allocation Comparison

Sectors	GERM	CANC
Healthcare	99.3%	100.0%
Financial Services	0.4%	-
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

GERM vs. CANC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CANC

CANC Risk / Return Rank: 69
CANC Sharpe Ratio Rank: 61
CANC Sortino Ratio Rank: 64
CANC Omega Ratio Rank: 54
CANC Calmar Ratio Rank: 90
CANC Martin Ratio Rank: 77

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GERM vs. CANC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Amplify Treatments, Testing and Advancements ETF (GERM) and Tema Oncology ETF (CANC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	GERM	CANC	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	2.06	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	-0.04	—

Drawdowns

GERM vs. CANC - Drawdown Comparison

The maximum GERM drawdown since its inception was 0.00%, smaller than the maximum CANC drawdown of -97.53%. Use the drawdown chart below to compare losses from any high point for GERM and CANC.

Drawdown Indicators

	GERM	CANC	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-97.53%	+97.53%
Max Drawdown (1Y) Largest decline over 1 year	0.00%	-8.67%	+8.67%
Max Drawdown (3Y) Largest decline over 3 years	—	-30.27%	—
Current Drawdown Current decline from peak	0.00%	-56.55%	+56.55%
Average Drawdown Average peak-to-trough decline	0.00%	-73.19%	+73.19%
Ulcer Index Depth and duration of drawdowns from previous peaks	0.00%	3.25%	-3.25%

Volatility

GERM vs. CANC - Volatility Comparison

The current volatility for Amplify Treatments, Testing and Advancements ETF (GERM) is 0.00%, while Tema Oncology ETF (CANC) has a volatility of 6.26%. This indicates that GERM experiences smaller price fluctuations and is considered to be less risky than CANC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GERM	CANC	Difference
Volatility (1M) Calculated over the trailing 1-month period	0.00%	6.26%	-6.26%
Volatility (6M) Calculated over the trailing 6-month period	0.00%	16.69%	-16.69%
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	23.11%	-23.11%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	280.27%	-280.27%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	280.27%	-280.27%

GERM vs. CANC - Expense Ratio Comparison

GERM has a 0.68% expense ratio, which is lower than CANC's 0.75% expense ratio.

Dividends

GERM vs. CANC - Dividend Comparison

GERM has not paid dividends to shareholders, while CANC's dividend yield for the trailing twelve months is around 0.05%.

Position	TTM	2025	2024	2023
CANC Tema Oncology ETF	0.05%	0.06%	3.00%	0.56%
GERM Amplify Treatments, Testing and Advancements ETF	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions

Which is riskier, GERM or CANC?

CANC has higher volatility (6.26%) compared to GERM (0.00%). In terms of maximum drawdown, GERM dropped 0.00% vs CANC's -97.53%.

Which ETF is better, GERM or CANC?

On 1-year performance, CANC leads with 47.37% vs 0.00% for GERM. On fees, GERM is cheaper at 0.68% per year. On volatility, GERM has been the lower-risk option at 0.00%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, GERM or CANC?

Over the 1-year period, CANC has performed better with a 47.37% return vs 0.00%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, GERM or CANC?

GERM is cheaper with a 0.68% expense ratio, compared with 0.75% for CANC.

Which ETF pays a higher dividend yield, GERM or CANC?

CANC has the higher dividend yield at 0.05%, compared with 0.00% for GERM.

What is the main difference between GERM and CANC?

They also come from different issuers: Amplify and Tema. Their fees differ too: 0.68% for GERM and 0.75% for CANC.